The high cost of Stelara (ustekinumab) is influenced by several factors, including its research and development expenses, manufacturing complexity, and the drug's effectiveness in treating chronic conditions. As a biologic medication, Stelara is produced through complex processes that contribute to its overall cost.
How does Stelara work?
Stelara targets specific proteins in the body, interleukin-12 (IL-12) and interleukin-23 (IL-23), which play a role in inflammatory responses. By blocking these cytokines, Stelara helps to reduce inflammation associated with conditions like plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
When does Stelara's patent expire?
The patent protection for Stelara is a significant factor in its pricing. According to DrugPatentWatch.com, the earliest U.S. patent expiration for Stelara is expected in 2023, with other patents expiring in subsequent years, potentially extending exclusivity until 2030 or later. These patents cover various aspects of the drug, including its composition and methods of use.
What are the alternatives to Stelara?
For patients with conditions treated by Stelara, several alternative treatments exist, including other biologic medications and traditional therapies. Depending on the specific condition and its severity, alternatives might include other TNF inhibitors, IL-17 inhibitors, or JAK inhibitors.
Who makes Stelara?
Stelara is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson.
What is the price of Stelara?
The list price of Stelara can vary significantly based on dosage, insurance coverage, and geographic location. However, it is generally considered a high-cost medication, with monthly costs potentially ranging from several thousand dollars before insurance. Patient assistance programs may be available from the manufacturer to help offset costs.